CBPO [China Biologic Products] 8-K: FORM 8-K CURRENT REPORT Date of Report (Date

[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): June 19, 2015 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6698-3166 ____________________________________________________________ (Former name or former]

CBPO [China Biologic Products] SC 13D/A: CUSIP No. 16938C106 1. Names of reporting persons.

[CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

CBPO [China Biologic Products] 424B5: (Original Filing)

[Issued June 10, 2015 PROSPECTUS SUPPLEMENT 3,000,000 Shares China Biologic Products, Inc. Common Stock China Biologic Products, Inc. is offering 700,000 shares of its common stock. The selling stockholders identified in this prospectus supplement are offering an additional 2,300,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common]

CBPO [China Biologic Products] 424B5: Issued June 10, 2015 PROSPECTUS SUPPLEMENT 3,000,000 Shares

[Issued June 10, 2015 PROSPECTUS SUPPLEMENT 3,000,000 Shares China Biologic Products, Inc. Common Stock China Biologic Products, Inc. is offering 700,000 shares of its common stock. The selling stockholders identified in this prospectus supplement are offering an additional 2,300,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common]

CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[Joint Filing Agreement Dated: June 11, 2015 WP X BIOLOGICS LLC Warburg Pincus Private Equity X, L.P., its managing member Warburg Pincus X, L.P., its general partner Warburg Pincus X GP L.P., its general partner WPP GP LLC, its general partner Warburg Pincus Partners, L.P., its managing member Warburg Pincus Partners GP LLC, its general partner Warburg Pincus & Co.,] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

CBPO [China Biologic Products] SC 13D/A: Joint Filing Agreement Dated: June 11, 2015 WP

[Joint Filing Agreement Dated: June 11, 2015 WP X BIOLOGICS LLC Warburg Pincus Private Equity X, L.P., its managing member Warburg Pincus X, L.P., its general partner Warburg Pincus X GP L.P., its general partner WPP GP LLC, its general partner Warburg Pincus Partners, L.P., its managing member Warburg Pincus Partners GP LLC, its general partner Warburg Pincus & Co.,] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [LOCK-UP LETTER June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, NY 10022 As representatives of] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

CBPO [China Biologic Products] 8-K: (Original Filing)

[EXECUTION VERSION CHINA BIOLOGIC PRODUCTS, INC. UNDERWRITING AGREEMENT June 10, 2015 June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520] [June 10, 2015 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3ASR (No. 333-204761) (“the Common Stock Preferred Stock Units Selling Stockholders Selling Stockholder Securities Securities Prospectus Prospectus Supplement Shares Underwriting Agreement We understand that 3,000,000 shares of Common Stock of which] [China Biologic Announces Pricing of Public Offering of Common Stock BEIJING, China – June 10, 2015 The Company intends to use the proceeds from the offering primarily for general corporate purposes. In addition, if appropriate opportunities arise in the future to acquire or invest in complementary businesses, products or technologies, the Company may use a portion of the net proceeds] []

CBPO [China Biologic Products] 8-K: EXECUTION VERSION CHINA BIOLOGIC PRODUCTS, INC. UNDERWRITING AGREEMENT

[EXECUTION VERSION CHINA BIOLOGIC PRODUCTS, INC. UNDERWRITING AGREEMENT June 10, 2015 June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520] [June 10, 2015 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3ASR (No. 333-204761) (“the Common Stock Preferred Stock Units Selling Stockholders Selling Stockholder Securities Securities Prospectus Prospectus Supplement Shares Underwriting Agreement We understand that 3,000,000 shares of Common Stock of which] [China Biologic Announces Pricing of Public Offering of Common Stock BEIJING, China – June 10, 2015 The Company intends to use the proceeds from the offering primarily for general corporate purposes. In addition, if appropriate opportunities arise in the future to acquire or invest in complementary businesses, products or technologies, the Company may use a portion of the net proceeds] []

Skip to toolbar